FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

FDA Withdraws 30 No-Longer-Marketed ANDAs

Federal Register notice: FDA withdraws approval of 30 abbreviated new drug applications from multiple applicants because the drug products are no long...

latest-news-card-1
Federal Register

OTC Monograph Drug User Fees

Federal Register notice: FDA announces the over-the-counter Monograph Drug User Fee Program facility fee rates for fiscal year 2024.

latest-news-card-1
FDA General

Weiner Moves to Foreign Inspections Office

FDA Office of Combination Products associate director for policy John Weiner moves to Office of Global Operations director, where he will oversee the ...

latest-news-card-1
Medical Devices

Boston Scientific Recalls PolarSheath Steerable

Boston Scientific recalls the PolarSheath Steerable Sheath 12F after the company identified a tooling error in manufacturing which may have caused del...

latest-news-card-1
Medical Devices

Magnetic Stimulation for Adolescent Depression Cleared

FDA clears a Neuronetics 510(k) for its NeuroStar Advanced Therapy for use as an adjunct for treating major depressive disorder in adolescent patients...

Medical Devices

FDA Approves Medtronic Evolut FX+

FDA approves the latest version of Medtronics Evolut FX+ system to treat symptomatic severe aortic stenosis.

latest-news-card-1
Human Drugs

2 REMS Assessment MAPPs

CDER publishes two MAPPs on elements of REMS assessments.

latest-news-card-1
Medical Devices

FDA Fails to Follow Science in Electroshock Case: Attorneys

Two attorneys who represented the Canton, MA-based Judge Rotenberg Center in its court case against FDAs efforts to ban the use of an electroshock or ...

latest-news-card-1
Biologics

BIO Suggestions for CGT Potency Guidance

The Biotechnology Innovation Organization suggests ways FDA can improve a draft guidance on potency assurance for cellular and gene therapy products.

latest-news-card-1
Human Drugs

Catalent Indiana FDA-483

FDA releases the form FDA-483 with six observations from an inspection at the Catalent Indiana drug manufacturing facility.